RecruitingNCT05712746
Samtasu Post-marketing General Drug Use-results Survey in Patients with Volume Overload in Heart Failure.
Sponsor
Otsuka Pharmaceutical Co., Ltd.
Enrollment
1,600 participants
Start Date
Mar 3, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
To confirm the safety of tolvaptan sodium phosphate in patients with volume overload in heart failure.
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- \-
Exclusion Criteria1
- patients with a known hypersensitivity to Tolvaptan sodium phosphate or Tolvaptan
Interventions
DRUGSamtasu for I.V. infusion
Drug: 8 mg/vial or 16mg/vial Dosage and Administration: The usual adult dosage of tolvaptan sodium phosphate is 16 mg once daily and intravenously infused over 1 hour.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05712746
Related Trials
Mind Your Heart-II
NCT054311921 location
Timing of Coronary Angiography in NSTEMI Complicated by Acute HF
NCT0700216420 locations
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288652 locations
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370641 locations
ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
NCT071917301 location